Literature DB >> 14532912

Nociceptin/orphanin FQ increases anxiety-related behavior and circulating levels of corticosterone during neophobic tests of anxiety.

Fabian Fernandez1, Michael A Misilmeri, Jennifer C Felger, Darragh P Devine.   

Abstract

Intracranial administration of nociceptin/orphanin FQ (N/OFQ) increases circulating concentrations of adrenocorticotrophic hormone and corticosterone in unstressed rats, and elevates the responsiveness of these hormones during mild stress. Furthermore, N/OFQ and its cognate receptor are both abundant in a variety of limbic nuclei, and stress exposure decreases neuronal N/OFQ content in forebrain neurons. In light of these and other findings, we examined the potential involvement of N/OFQ in regulation of anxiety-related behaviors in rats. In the open field, elevated plus maze, and dark-light neophobic tests, intracerebroventricular N/OFQ (1.0 pmole-1.0 nmole) increased the expression of anxiety-related behaviors. Specifically, N/OFQ increased the latency to enter, decreased the number of entries into, and decreased the time spent in the exposed or brightly lit environments of all three tests. N/OFQ also enhanced thigmotactic responses in the open field test. The effects of diazepam and of the benzodiazepine inverse agonist FG 7142 were also assessed in independent groups of rats. In all three tests, the behavioral effects of N/OFQ resembled the anxiogenic actions of FG 7142, and contrasted with the anxiolytic actions of diazepam. N/OFQ administration also increased circulating concentrations of corticosterone during anxiety testing, in comparison with the concentrations in vehicle-treated controls. We conclude that N/OFQ administration is anxiogenic, and elevates responsiveness of the hypothalamic pituitary-adrenal axis during neophobic tests of anxiety. This supports the possibility that N/OFQ neurotransmission participates in processing of emotionally-salient and stressful stimuli, and suggests that normal functioning of the N/OFQ system may be important in physiological and psychological well-being.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14532912     DOI: 10.1038/sj.npp.1300308

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  31 in total

1.  Experimental sleep fragmentation and sleep deprivation in rats increases exploration in an open field test of anxiety while increasing plasma corticosterone levels.

Authors:  Jaime L Tartar; Christopher P Ward; Joshua W Cordeira; Steven L Legare; Amy J Blanchette; Robert W McCarley; Robert E Strecker
Journal:  Behav Brain Res       Date:  2008-09-02       Impact factor: 3.332

2.  The effects of new nociceptin analogs on the behavior of white rats.

Authors:  E A Chesnokova; P K Anokhin; A S Voronkova; N Yu Sarycheva; V A Dubynin; A A Kamenskii; L A Andreeva; N F Myasoedov
Journal:  Dokl Biol Sci       Date:  2013-05-08

3.  Modification of anxiety-like behaviors by nociceptin/orphanin FQ (N/OFQ) and time-dependent changes in N/OFQ-NOP gene expression following ethanol withdrawal.

Authors:  Harinder Aujla; Rosalia Cannarsa; Patrizia Romualdi; Roberto Ciccocioppo; Rémi Martin-Fardon; Friedbert Weiss
Journal:  Addict Biol       Date:  2012-07-15       Impact factor: 4.280

4.  Further characterization of the prototypical nociceptin/orphanin FQ peptide receptor agonist Ro 64-6198 in rodent models of conflict anxiety and despair.

Authors:  Celia Goeldner; Will Spooren; Jürgen Wichmann; Eric P Prinssen
Journal:  Psychopharmacology (Berl)       Date:  2012-01-18       Impact factor: 4.530

5.  Lateral habenular norepinephrine contributes to states of arousal and anxiety in male rats.

Authors:  Erin M Purvis; Adam K Klein; Aaron Ettenberg
Journal:  Behav Brain Res       Date:  2018-03-09       Impact factor: 3.332

6.  Beta-arrestin 2 rather than G protein efficacy determines the anxiolytic-versus antidepressant-like effects of nociceptin/orphanin FQ receptor ligands.

Authors:  L Asth; C Ruzza; D Malfacini; I Medeiros; R Guerrini; N T Zaveri; E C Gavioli; G Calo'
Journal:  Neuropharmacology       Date:  2016-02-08       Impact factor: 5.250

Review 7.  The cognitive cost of sleep lost.

Authors:  John G McCoy; Robert E Strecker
Journal:  Neurobiol Learn Mem       Date:  2011-08-22       Impact factor: 2.877

Review 8.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

Review 9.  Antidepressant- and anxiolytic-like effects of nociceptin/orphanin FQ receptor ligands.

Authors:  Elaine C Gavioli; Girolamo Calo'
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-02-21       Impact factor: 3.000

10.  Novel Synthesis and Pharmacological Characterization of NOP Receptor Agonist 8-[(1S,3aS)-2,3,3a,4,5,6-Hexahydro-1H-phenalen-1-yl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one (Ro 64-6198).

Authors:  Steven D Chang; Lawrence E Brieaddy; Joseph D Harvey; Anita H Lewin; S Wayne Mascarella; Herbert H Seltzman; P Anantha Reddy; Ann M Decker; Charles J McElhinny; Desong Zhong; Elisha E Peterson; Hernán A Navarro; Michael R Bruchas; F Ivy Carroll
Journal:  ACS Chem Neurosci       Date:  2015-09-30       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.